Boundless bio, inc. BOLD.US Overview
BOLD AI Analysis & Strategy
Analysis Conclusion
The stock has a low value rating. If your investment strategy is value-oriented and you have long-term positions, it's crucial to adhere to your exit plan and consider reducing holdings.
BOLD Current Performance
0.92%
Boundless bio, inc.
2.83%
Avg of Sector
-0.07%
S&P500
BOLD Key Information
BOLD Financial Forecast
Unit : USD
BOLD Earnings Table
BOLD Profile
Boundless Bio, Inc., a clinical-stage oncology company, develops cancer therapeutics to address the unmet need of patients with oncogene amplified tumors by targeting extrachromosomal DNA. Its lead product candidate is BBI-355, an oral inhibitor of checkpoint kinase 1 that is in Phase 1/2 clinical trial in patients with oncogene amplified cancers. The company is also developing BBI-825, an oral inhibitor of ribonucleotide reductase, which is in Phase 1/2 clinical trial in cancer patients with resistance gene amplifications; and ecDTx 3 program targeting a kinesin involved with the cellular mechanism for segregation of ecDNA. Boundless Bio, Inc. was formerly known as Pretzel Therapeutics, Inc. and changed its name to Boundless Bio, Inc. in July 2019. The company was incorporated in 2018 and is headquartered in San Diego, California.
Price of BOLD
BOLD FAQ
When is BOLD's latest earnings report released?
The most recent financial report for Boundless bio, inc. (BOLD) covers the period of 2025Q1 and was published on 2025/03/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating BOLD’s short-term business performance and financial health. For the latest updates on BOLD’s earnings releases, visit this page regularly.
How much debt does BOLD have?
As of the end of the reporting period, Boundless bio, inc. (BOLD) had total debt of 48.57M, with a debt ratio of 0.25. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company’s capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.
How much cash does BOLD have?
At the end of the period, Boundless bio, inc. (BOLD) held Total Cash and Cash Equivalents of 15.68M, accounting for 0.08 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
Is BOLD's EPS continuing to grow?
According to the past four quarterly reports, Boundless bio, inc. (BOLD)’s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.71. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.
What is the FCF of BOLD?
Boundless bio, inc. (BOLD)’s Free Cash Flow (FCF) for the period is -14.59M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 8.01% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.
What are the PEG ratio and PE ratio of BOLD?
The latest valuation data shows Boundless bio, inc. (BOLD) has a Price-To-Earnings (PE) ratio of -0.49 and a Price/Earnings-To-Growth (PEG) ratio of 0.03. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.